SG11201804473RA - Pd-1 signal inhibitor combination therapy - Google Patents

Pd-1 signal inhibitor combination therapy

Info

Publication number
SG11201804473RA
SG11201804473RA SG11201804473RA SG11201804473RA SG11201804473RA SG 11201804473R A SG11201804473R A SG 11201804473RA SG 11201804473R A SG11201804473R A SG 11201804473RA SG 11201804473R A SG11201804473R A SG 11201804473RA SG 11201804473R A SG11201804473R A SG 11201804473RA
Authority
SG
Singapore
Prior art keywords
combination therapy
substances
signal inhibitor
inhibitor combination
iii
Prior art date
Application number
SG11201804473RA
Inventor
Tasuku Honjo
Kenji Chamoto
Sidonia Fagarasan
Original Assignee
Univ Kyoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kyoto filed Critical Univ Kyoto
Publication of SG11201804473RA publication Critical patent/SG11201804473RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMBINATION THERAPY BASED ON PD-1 SIGNAL INHIBITORS A novel therapeutic strategy for the anti-PD-1 antibody therapy is provided. A pharmaceutical composition which comprises at least one substance selected from the group consisting of the following (i) to (iii) and is administered before, after or simultaneously with the administration of a PD-1 signal inhibitor: (i) ROS generators and substances that regulate downstream signaling pathways thereof, (ii) substances exhibiting an uncoupling effect and substances that regulate downstream signaling pathways thereof, and (iii) amino acids. [Figure 1]
SG11201804473RA 2015-12-07 2016-12-05 Pd-1 signal inhibitor combination therapy SG11201804473RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015238511 2015-12-07
JP2016119695 2016-06-16
PCT/JP2016/086045 WO2017099034A1 (en) 2015-12-07 2016-12-05 Pd-1 signal inhibitor combination therapy

Publications (1)

Publication Number Publication Date
SG11201804473RA true SG11201804473RA (en) 2018-06-28

Family

ID=59014100

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201804473RA SG11201804473RA (en) 2015-12-07 2016-12-05 Pd-1 signal inhibitor combination therapy
SG10202006032VA SG10202006032VA (en) 2015-12-07 2016-12-05 Combination therapy based on pd-1 signal inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202006032VA SG10202006032VA (en) 2015-12-07 2016-12-05 Combination therapy based on pd-1 signal inhibitors

Country Status (13)

Country Link
US (3) US20180362650A1 (en)
EP (2) EP3388084A4 (en)
JP (1) JP6994240B2 (en)
KR (1) KR20180093990A (en)
CN (3) CN114404595A (en)
AU (1) AU2016366250A1 (en)
BR (1) BR112018011131A2 (en)
CA (1) CA3007613A1 (en)
IL (1) IL259857A (en)
MX (1) MX2018006518A (en)
SG (2) SG11201804473RA (en)
TW (1) TW201726169A (en)
WO (1) WO2017099034A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222949A1 (en) 2017-06-01 2018-12-06 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
AU2018302656A1 (en) * 2017-07-20 2020-01-16 Fuso Pharmaceutical Industries,Ltd. Combination use of inhibitor targeting PD-1/PD-L1 and COX-2 inhibitor
TWI796596B (en) 2018-02-13 2023-03-21 美商基利科學股份有限公司 Pd-1/pd-l1 inhibitors
US20210082111A1 (en) * 2018-03-29 2021-03-18 Sony Corporation Information processing device, information processing method, and program
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR20230159715A (en) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 inhibitors
KR102635333B1 (en) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 PD-1/PD-L1 inhibitors
WO2020169707A1 (en) * 2019-02-21 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Foxo1 inhibitor for use in the treatment of latent virus infection
RU2731293C1 (en) 2019-04-12 2020-09-01 Игорь Петрович Белецкий Method of producing genetically modified lines of cells of natural killers with knockout pd-1 gene and high expression of proteins of family of tumour necrosis factor for immunotherapy of oncological diseases
WO2021095599A1 (en) * 2019-11-13 2021-05-20 国立大学法人京都大学 Pd-1 signal inhibitor combination therapy
EP4204008A1 (en) 2020-08-26 2023-07-05 Citius Pharmaceuticals, Inc. Combination for use in methods of treating cancer
CN112472710A (en) * 2020-11-05 2021-03-12 中国人民解放军海军军医大学 Application of nicotinamide adenine dinucleotide precursor in preparation of anti-tumor sensitization medicine of immune checkpoint inhibitor
WO2022197554A1 (en) * 2021-03-16 2022-09-22 University Of Massachusetts Photocaged citrulline analogs and methods for site-specific incorporation of citrulline into proteins
CN113069529A (en) * 2021-04-16 2021-07-06 郑州大学第一附属医院 Use of GSH in combination with PD-1/PD-L1 blockers for promoting CD8+Use of T cell function
WO2023076880A1 (en) * 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
CN115414343B (en) * 2022-09-29 2023-11-21 中南大学湘雅医院 Application of alpha-ketoglutaric acid and derivatives thereof and medicine for preventing and treating skin tumor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383224C (en) * 1999-09-21 2010-12-07 Geetha Ghai Extracts of orange peel for prevention and treatment of cancer
KR20030067935A (en) * 2002-02-09 2003-08-19 김상건 Pharmaceutical Composition Comprising Oltipraz for Regeneration of Cirrhotic Liver
US20150329617A1 (en) * 2001-03-14 2015-11-19 Dynal Biotech Asa Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules
CN1329030C (en) * 2002-12-26 2007-08-01 味之素株式会社 Inhibitor for liver cancer onset and progress
JP5248747B2 (en) * 2006-01-19 2013-07-31 キッセイ薬品工業株式会社 Adiponectin receptor expression activator
JP6041333B2 (en) * 2011-01-13 2016-12-07 学校法人近畿大学 Antitumor agent
WO2014009222A1 (en) * 2012-07-10 2014-01-16 Basilea Pharmaceutica Ag Combination therapy for the treatment of cancer and immunosuppression
AU2013318338B2 (en) * 2012-09-21 2017-05-25 Intensity Therapeutics, Inc Method of treating cancer
KR20240017102A (en) 2013-12-17 2024-02-06 제넨테크, 인크. Methods of treating cancers using pd-1 axis binding antagonists and taxanes
JP6104417B2 (en) 2016-02-02 2017-03-29 キヤノン株式会社 Control device, control method, and program

Also Published As

Publication number Publication date
EP3388084A1 (en) 2018-10-17
SG10202006032VA (en) 2020-07-29
CA3007613A1 (en) 2017-06-15
MX2018006518A (en) 2019-01-10
KR20180093990A (en) 2018-08-22
WO2017099034A1 (en) 2017-06-15
CN114601930A (en) 2022-06-10
TW201726169A (en) 2017-08-01
JPWO2017099034A1 (en) 2018-11-01
EP3388084A4 (en) 2019-11-13
US20230272077A1 (en) 2023-08-31
JP6994240B2 (en) 2022-02-04
EP4218819A3 (en) 2023-08-23
US20180362650A1 (en) 2018-12-20
IL259857A (en) 2018-07-31
CN114404595A (en) 2022-04-29
BR112018011131A2 (en) 2018-11-21
AU2016366250A1 (en) 2018-06-14
US20230265193A1 (en) 2023-08-24
CN108601840A (en) 2018-09-28
EP4218819A2 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
SG11201804473RA (en) Pd-1 signal inhibitor combination therapy
EP4269440A3 (en) Composition for treating il-6-related diseases
PH12015502002B1 (en) Tripeptide epoxy ketone protease inhibitors
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
WO2013003629A3 (en) Methods and compositions for inhibition of bone resorption
MX2018015302A (en) Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same.
EA201490653A1 (en) DERIVATIVES ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDE, METHOD FOR THEIR PRODUCTION CONTAINING THEIR PHARMACEUTICAL PREPARATIONS
JO3326B1 (en) Tripeptide Epoxy Ketone Protease Inhibitors
MX2018005715A (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer.
BR112013021566A2 (en) compound of formula, or a pharmaceutically acceptable salt or adduct thereof and method of preventing and / or treating an individual comprising administering to said individual a therapeutically effective amount of a compound of formula
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
MX2022015629A (en) Use of vibegron to treat overactive bladder.
MX2017013636A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from different particles.
NZ735777A (en) Methods and compositions to inhibit symptoms associated with veisalgia
MX2016012784A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions.
WO2014194226A3 (en) Methods of treatment and compositions with xanthine oxidase inhibitors
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
MY192813A (en) Aqueous formulation comprising paracetamol and ibuprofen
MY193996A (en) Tripeptide compound, preparation method therefor, and application thereof
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
BR112015001627A2 (en) pharmaceutical composition, their uses and method of decreasing the frequency of urination
MY193963A (en) Composition for treating joint diseases and kit containing same
MX2016016039A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof.
BR112015032534A2 (en) uses of the compound or pharmaceutically acceptable salt, solvate or prodrug thereof, pharmaceutical compositions and methods for preventing and / or treating chronic traumatic encephalopathy or related condition in an individual and for treating an individual with concussion injury
MX2017013633A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles.